

Study of vision achieved with two contact lenses to correct presbyopia (the gradual loss of your eyes' ability to focus on nearby objects)

Submission date 28/01/2021	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 29/01/2021	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 03/02/2021	Condition category Eye Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Presbyopia is the gradual loss of your eyes' ability to focus on nearby objects. It's a natural, often annoying part of ageing. Presbyopia usually becomes noticeable in your early to mid-40s and continues to worsen until around age 65.

Multifocal contact lenses (contact lenses that correct both distance and near vision for people who need reading glasses) come in very different designs some giving better vision at near or at distance. In order to improve this type of contact lenses it is important to compare how well different designs are tolerated by patient and correct vision.

The study compares the level of vision satisfaction and the visual acuity achieved by two different contact lenses designs currently available.

Who can participate?

Adults who are at least 40 years old and who have healthy eyes and are current multifocal contact lens wearers.

What does the study involve?

Each participant attends the clinic on three occasions. At the first visit after being screened and enrolled in the study, their eyes are examined and they are fitted and dispensed with one of the two study contact lenses (which lens pair is used first is randomly determined like tossing a coin). The second visit takes place one week after the first, during that visit the contact lens which the participant wore are assessed. Then, the participant is fitted and dispensed with the other contact lens pair, which they wear for one week. At the third and final visit, the contact lenses that have been worn are assessed and the participant is discharged from the study.

What are the possible benefits and risks of participating?

The participants will have the opportunity to try two different types of multifocal contact lenses which they may prefer to their own multifocal contact lenses and at a later date may decide to opt for these lenses. The two contact lens types are CE marked and therefore the risks are no different to them wearing their own contact lenses.

Where is the study run from?

Ocular Technology Group - International Research Clinic (UK)

When is the study starting from and how long is it expected to run for?

October 2018 to June 2019

Who is funding the study?

CooperVision Inc (USA)

Who is the main contact?

Deborah Moore

dmoore@otg.co.uk

Contact information

Type(s)

Public

Contact name

Ms Deborah Moore

Contact details

66 Buckingham Gate

London

United Kingdom

SW1E 6AU

+44 (0)2072224224

dmoore@otg.co.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

263503

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

IRAS 263503, ID19-08 CV19-29

Study information

Scientific Title

Clariti® multifocal contact lens performance study

Study objectives

The overall visual acceptance with the two near addition system will not be inferior to the three near addition system.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 23/04/2019, London - Stanmore Research Ethics Committee (Skipton House, 80 London Road, London, SE1 6LH, UK; +44 (0)207 972 2561; stanmore.rec@hra.nhs.uk), ref: 19/LO/0574

Study design

Single-centre prospective randomised (testing order) double-masked cross over study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Presbyopia vision correction using multifocal contact lenses

Interventions

The study is a cross over study, the participants wear two CE-marked multifocal contact lenses each for a period of 7 +2/-0 days:

1. clariti® 1-day multifocal (test)
2. MyDay® multifocal combined with clariti® 1-day multifocal (control)

The order of testing will be randomised using a standard computerised randomisation software.

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Contact lenses, MyDay® multifocal, clariti® 1-day multifocal

Primary outcome(s)

Overall binocular vision satisfaction measured on a 100-point visual analogue scale (VAS) after 1 week of wear

Key secondary outcome(s)

Overall binocular visual performance measured by LogMAR visual acuity after 1 week of wear

Completion date

14/06/2019

Eligibility

Key inclusion criteria

1. Aged at least 40 years
2. Have read and understood the Participant Information Sheet
3. Have read, signed and dated the Informed Consent
4. Best corrected visual acuity of at least 20/25 in each eye
5. Have normal eyes with the exception of the need for visual correction
6. Current multifocal contact lens wearer
7. Spectacle refraction:
Distance: Sphere: -6.00D to + 4.00D
Astigmatism: 0.00D to -0.75D
Near Addition: +0.75 to 2.50D
8. Be willing and able to adhere to the instructions set in the clinical protocol and maintain the appointment schedule

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

20

Key exclusion criteria

1. Ocular anterior segment infection, inflammation, abnormality, or active disease that would contraindicate contact lens wear
2. Newly prescribed use of some systemic or ocular medications for which contact lens wear could be contraindicated as determined by the investigator
3. Monocular participants (only one eye with functional vision) or participants fit with only one lens
4. Any moderate or severe ocular condition observed during the slit-lamp examination at the enrolment visit
5. History of herpetic keratitis, ocular surgery or irregular cornea
6. Known pregnancy or lactation during the study period
7. Enrolment of the investigator or his/her staff, family members of the investigator, family members of the investigator's staff, or individuals living in the households of these individuals

Date of first enrolment

25/04/2019

Date of final enrolment

07/06/2019

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Ocular Technology Group - International

66 Buckingham Gate

London

United Kingdom

SW1E 6AU

Sponsor information

Organisation

CooperVision (United States)

Funder(s)

Funder type

Industry

Funder Name

CooperVision Inc. (USA)

Results and Publications

Individual participant data (IPD) sharing plan

The current data sharing plans for this study are unknown and will be available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results		03/02/2021	03/02/2021	No	No
HRA research summary			28/06/2023	No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes